Research on Asian patients with heart failure with reduced ejection fraction (HFrEF) explored the prescription patterns and doses attained of guideline-directed medical therapies in Asian HFrEF patients, and the associations with patient outcomes.
Southeast Asia is seeing a rise in the risk factors of heart failure which will inevitably increase the epidemic of heart failure. In a first-ever prospective, multinational real-world data examination of prescription patterns and doses attained of guideline-directed medical therapies in Asian patients suffering from heart failure with reduced ejection fraction (HFrEF), a team of researchers studied the prescription patterns and doses attained of guideline-directed medical therapies in Asian HFrEF patients, and the associations with patient outcomes. The research findings provided valuable insights into the importance of guideline recommendations to prescribe evidence-based therapies to achieve maximum benefits among Asian patients with HFrEF. They also highlighted the gaps in knowledge and treatment.
Click here for the full article (in Mandarin).
